Prodrugs of amino quinazoline kinase inhibitor

Abstract

Disclosed are compounds having the formula: wherein X is as defined herein, and methods of making and using the same.

What is claimed is: 
     
         1 . A compound which is: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         2 . A compound of  claim 1 , which is (2S,3S)-2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl 2-amino-3-methylpentanoate. 
     
     
         3 . The compound, or pharmaceutically acceptable salt thereof, according to  claim 1 , which is the pharmaceutically acceptable salt of said compound. 
     
     
         4 . A pharmaceutical composition comprising the compound, or pharmaceutically acceptable salt thereof, according to  claim 1 , and a pharmaceutically acceptable excipient. 
     
     
         5 . A method of treating a disease mediated by RIP2 kinase comprising administering a therapeutically effective amount of the compound, or pharmaceutically acceptable salt thereof, or hydrate thereof, according to  claim 1  to a human in need thereof, wherein the disease is selected from uveitis, dermatitis, acute lung injury, type 2 diabetes mellitus, arthritis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, early-onset inflammatory bowel disease, extraintestinal inflammatory bowel disease, prevention of ischemia reperfusion injury in solid organ transplant, non-alcohol steatohepatitis, autoimmune hepatitis, asthma, systemic lupus erythematosus, multiple sclerosis, sarcoidosis, Blau syndrome/early-onset sarcoidosis, Wegner's granulomatosis, and interstitial pulmonary disease. 
     
     
         6 . The method according to  claim 5 , wherein the disease is selected from uveitis, Blau Syndrome, early-onset sarcoidosis, ulcerative colitis, Crohn's disease, Wegener's granulamatosis and sarcoidosis. 
     
     
         7 . The method according to  claim 5 , wherein the disease is Crohn's disease. 
     
     
         8 . The method according to  claim 5 , wherein the disease is ulcerative colitis. 
     
     
         9 . The method according to  claim 5 , wherein the disease is Blau syndrome. 
     
     
         10 . The method according to  claim 5 , wherein the disease is rheumatoid arthritis.